Clinical trialNCT02052739CompletedPhase 1/PHASE2Interventional

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

SponsorSupernus Pharmaceuticals, Inc.Enrollment25Super-refractory Status Epilepticus

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Robert Lasser, MD, MBA
Sage Therapeutics
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Sage Investigational Site
Birmingham, Alabama, United States
Sage Investigational Site
Sarasota, Florida, United States
Sage Investigational Site
Chicago, Illinois, United States
Sage Investigational Site
Wichita, Kansas, United States
Sage Investigational Site
New Orleans, Louisiana, United States
Sage Investigational Site
Boston, Massachusetts, United States
Sage Investigational Site
Boston, Massachusetts, United States
Sage Investigational Site
Ann Arbor, Michigan, United States
Sage Investigational Site
Detroit, Michigan, United States
Sage Investigational Site
New York, New York, United States
Sage Investigational Site
Rochester, New York, United States
Sage Investigational Site
Durham, North Carolina, United States
Sage Investigational Site
Winston-Salem, North Carolina, United States
Sage Investigational Site
Philadelphia, Pennsylvania, United States
Sage Investigational Site
Nashville, Tennessee, United States
Sage Investigational Site
Dallas, Texas, United States
Sage Investigational Site
Temple, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

SAGE-547

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Mar 2014
Primary completion: 3 May 2015
Completion: 3 May 2015
Last update posted: 15 Sept 2025
Registered enrollment: 25
Registry id: NCT02052739

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.